CompletedNot Applicable

Specialized Proresolving Mediators in Pneumocystis Jirovecii Pneumonia

France66 participantsStarted 2018-10-01

Plain-language summary

This study aims to evaluate specialized proresolving mediators (SPM) concentrations for the first time in subjects infected with Pneumocystis jirovecii. SPM will be measured in blood and urine in patients with favourable or unfavourable outcome of Pneumocystis pneumonia and in patients colonized by Pneumocystis jirovecii. The hypothesis is that low levels of SPM in the blood could be predictive of a negative outcome of pneumocystosis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient over 18 years old * Patient with a social security cover. * Free and informed oral consent given. * Pneumocystis infection or colonization diagnosed on BAL (Broncho-alveolar liquid) or sputum at Toulouse University hospital Mycology laboratory. * Adequate Pneumocystis therapy for infected patients (cotrimoxazole). Exclusion Criteria: * individuals placed under juridical protection, * individuals placed under guardianship, or supervision. * Pregnancy or breastfeeding.

What they're measuring

14,15-DHET blood level at the inclusio

Timeframe: Day 0

14,15-DHET blood level

Timeframe: Day 7

Trial details

NCT IDNCT03606252

SponsorUniversity Hospital, Toulouse

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-03-12

View on ClinicalTrials.gov More Pneumonia, Pneumocystis trials